Solid Tumor Immunotherapy with T Cell Engager-Armed Oncolytic Viruses.

Area of Science:

• Oncology
• Immunotherapy
• Virology

Background:

• Oncolytic viruses (OVs) are emerging as potent anticancer agents, capable of direct tumor cell lysis and immune system activation.
• Bispecific T cell engagers (BiTEs) redirect T cells to target cancer cells, showing success in hematological malignancies but facing challenges in solid tumors due to delivery and toxicity issues.

Purpose of the Study:

• To explore the potential of engineering oncolytic viruses (OVs) to produce bispecific T cell engagers (BiTEs) directly within tumors.
• To address the limitations of BiTEs in solid tumors, including poor tumor penetration and on-target, off-tumor toxicities.

Main Methods:

• Review of preclinical data on the development of BiTE-armed OVs.
• Discussion of strategies for linking BiTE production to OV replication within tumor cells.
• Exploration of cotargeting cancer cells and associated stromal cells.

Main Results:

• Arming OVs with BiTEs restricts therapeutic agent production to the tumor site, enhancing safety and efficacy.
• This approach synergizes direct oncolysis with T cell-mediated cytotoxicity, improving treatment outcomes.
• Preclinical studies indicate significant potential for BiTE-armed OVs in treating solid tumors.

Conclusions:

• BiTE-armed OVs represent a novel multimodal therapeutic strategy with a widened therapeutic window for solid tumors.
• This approach holds promise for overcoming the challenges associated with traditional BiTE delivery and toxicity.
• Future research may focus on cotargeting tumor cells and stromal components for enhanced therapeutic effects.